Corcept Therapeutics Inc. (NASDAQ: CORT) is one of the 10 best biotech stocks with highest upside potential.

Quick Read Cytokinetics launched FDA-approved MYQORZO in December 2025 with Q4 revenue of $17.75M beating consensus by 121%; ...

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

Eli Lilly’s run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax ...

Locking in profits while you have them can help avoid downturns.

Following a turbulent year for the markets in general and biotech in particular, the industry made a notable recovery, ...

CLEVELAND, Ohio— The Cleveland biotech start-up Asclepii, founded in a college dorm room, is seeking to change lives for ...

Biopharma is rebounding across rare disease, oncology and neuroscience. Here, Cytokinetics achieved a rare milestone: a first ...

While several major biotech companies are laying off employees by the hundreds, one is dropping billions in acquisitions.

In its SEC prospectus, Hemab says it intends to use the net proceeds, together with existing cash, to fund clinical ...

After Xoma Royalty went on a dealmaking spree last year, the biotech royalty aggregator is now itself being bought out by its ...

ORLANDO, FL / ACCESS Newswire / April 20, 2026 / RedChip Companies, an industry leader in investor relations, media, ...